A Study of Tirzepatide (LY3298176) in Pediatric Participants With Obesity

NCT05696847 · Completed

Last updated 2026-05-28

This study tests the safety of the medication tirzepatide in children and adolescents who have obesity.

Status Completed The study has finished.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design Randomized, double-blind basic-science study

Participants 28 people

Who can join Ages 6–11 · all sexes

Timeline Started 2023-02 · est. completion 2025-01

Where 3 sites · United States

What this study is testing ClinicalTrials.gov NCT05696847 ↗

Description as written by the study sponsor.

The main purpose of this study is to evaluate the safety and tolerability of tirzepatide (LY3298176) in pediatric participants with obesity. The blood tests will be performed to investigate how the body processes the study drug in these participants. For each participant, the study will last about approximately 13 weeks excluding the screening period.

Treatments tested

Tirzepatide also known as LY3298176 Drug

Administered SC
Placebo Drug

Administered SC

Main thing measured	Percentage of Participants With One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs)
Sponsor	Eli Lilly and Company
Conditions studied	Obesity
GLP-1 drugs	tirzepatide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT05696847 ↗